<- Go Home
Agilent Technologies, Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. This segment also offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies. The Diagnostics and Genomics segment provides genomics, contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses; and cell analysis plate based assays, flow cytometers, real-time cell analyzers, cell imaging systems, microplate readers, and related consumables. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Market Cap
$42.4B
Volume
1.7M
Cash and Equivalents
$1.3B
EBITDA
$1.8B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$3.5B
Profit Margin
54.30%
52 Week High
$155.35
52 Week Low
$124.16
Dividend
0.67%
Price / Book Value
7.19
Price / Earnings
33.55
Price / Tangible Book Value
48.50
Enterprise Value
$44.6B
Enterprise Value / EBITDA
24.04
Operating Income
$1.5B
Return on Equity
21.95%
Return on Assets
8.54
Cash and Short Term Investments
$1.3B
Debt
$3.6B
Equity
$5.9B
Revenue
$6.5B
Unlevered FCF
$1.2B
Sector
Life Sciences Tools and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium